NCT06563375View on ClinicalTrials.gov

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions
Solid Tumor
Interventions
DRUG

NP-101

Given by mouth

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Novatek Pharmaceuticals, Inc.

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06563375 - Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter